Scott WenderferChair
William SmoyerCo-Chair


Meredith Atkinson
Guillermo Hidalgo
Shahnaz Shahinfar
Joyce Samuel
Debbie Gipson
Lorena Botero-Calderon
Larysa Wickman


  • To develop collaborative relationships and standardized processes among the NIH, FDA, Patient Advocacy Groups, Academia, and Industry to facilitate and accelerate pediatric nephrology clinical trial enrollment and completion. The main goal is to enhance communication among all the groups.


This part of the ASPN web site is established by the ASPN Therapeutics Development Committee (TDC) to support the development and conduct of clinical trials in pediatric nephrology and beyond. It is open to the public to provide the pediatric research community with information on planning and conducting clinical trials. We plan to regularly update both this explanation and the content contained herein.

Toward these ends, we are posting two figures from an article about the TDC, published in Pediatric Research (Schnaper, et al, Pediatric Research 82(5) p727-732, 2017). Figure 1 shows the approach to clinical trials as defined by pediatric nephrologists. Figure 2 shows a similar approach from the point of view of industry. While these figures are static, we plan in the near future to make them dynamic, so that in selecting and clicking on a box in the figure, the searcher can bring up information describing how to conduct an activity or obtain contact information for people or agencies that can facilitate that activity.

Gudiance of Clinical Trials During COVID-19 Pandemic

Community Posts

Please log in to view this content